(Q47643591)

English

Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an explora

scientific article published on 7 June 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an explora (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

1 reference

based on heuristic

inferred from title

Bradley J. Monk

3

object named as

Bradley J Monk

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

author name string

Dana M Chase

1

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

Michael W Sill

2

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

Mark D Chambers

4

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

Kathleen M Darcy

5

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

Ernest S Han

6

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

Barbara J Buening

7

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

Joel I Sorosky

8

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

John P Fruehauf

9

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

Robert A Burger

10

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

language of work or name

0 references

publication date

7 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

126

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

3

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

375-380

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

Overview of anti-angiogenic agents in development for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.002

7 January 2021

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.002

7 January 2021

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.002

7 January 2021

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.002

7 January 2021

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.002

7 January 2021

The Proof and Measurement of Association between Two Things

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.002

7 January 2021

The role of dynamic contrast-enhanced and diffusion weighted magnetic resonance imaging in the female pelvis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.002

7 January 2021

Imaging ovarian cancer and peritoneal metastases--current and emerging techniques

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.002

7 January 2021

Normalization of the vasculature for treatment of cancer and other diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.002

7 January 2021

Identifiers

10.1016/J.YGYNO.2012.06.002

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/22683587

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47643591&oldid=2032768723"